BridgeBio Pharma, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Three exhibits contain standard Sarbanes-Oxley certifications signed by Neil Kumar (CEO), Thomas Trimarchi (CFO), and Maricel M. Apuli (Chief Accounting Officer) dated August 10, 2026, certifying the accuracy of financial statements, effectiveness of disclosure controls, and absence of fraud for the quarter ended June 30, 2026. No material changes, transactions, or financial data are disclosed in these certification documents.
Why this rating
Boilerplate SOX 302/906 certifications are mandatory quarterly filings containing no substantive business information, transaction details, or financial metrics. Routine compliance disclosure.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.